Heliox inhalation therapy for bronchiolitis in infants.

Area of Science:

• Pediatrics
• Pulmonology
• Critical Care Medicine

Background:

• Bronchiolitis is a leading cause of infant hospitalization in high-income countries, characterized by airway obstruction.
• Heliox, an oxygen-helium mixture, may improve airflow and reduce breathing effort in infants with respiratory distress.

Purpose of the Study:

• To evaluate the efficacy of heliox inhalation therapy as an adjunct to standard care for acute bronchiolitis in infants.
• Key endpoints included intubation rates, emergency department discharge rates, length of respiratory distress treatment, and clinical respiratory scores.

Main Methods:

• A systematic review of randomized controlled trials (RCTs) and quasi-RCTs was conducted.
• Searches included CENTRAL, MEDLINE, EMBASE, LILACS, and the NIH website up to March 2015.
• Data extraction and quality assessment were performed independently by two reviewers.

Main Results:

• Seven trials involving 447 infants were analyzed; most were in pediatric intensive care units.
• Heliox did not significantly reduce intubation rates or overall length of treatment for respiratory distress.
• A significant reduction in clinical respiratory scores was observed within the first hour of treatment (moderate quality evidence).
• Heliox therapy reduced treatment length in a subgroup of infants requiring nasal continuous positive airway pressure (nCPAP).

Conclusions:

• Heliox therapy may offer short-term benefits by improving clinical respiratory scores in infants with acute bronchiolitis.
• Evidence does not support heliox for reducing intubation rates or overall hospital stay.
• Further research with standardized heliox application protocols and defined severity criteria is needed to clarify its role in severe bronchiolitis management.